Last reviewed · How we verify
PEG- 400 based artificial tear
PEG-400 based artificial tear lubricates and protects the ocular surface by forming a protective film that retains moisture and reduces friction.
PEG-400 based artificial tear lubricates and protects the ocular surface by forming a protective film that retains moisture and reduces friction. Used for Dry eye disease / Keratoconjunctivitis sicca.
At a glance
| Generic name | PEG- 400 based artificial tear |
|---|---|
| Sponsor | Bp Consulting, Inc |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Polyethylene glycol (PEG-400) is a hydrophilic polymer that acts as a lubricant and demulcent on the corneal and conjunctival surfaces. It increases tear film viscosity and stability, reducing evaporation and providing prolonged ocular surface hydration. This mechanism alleviates symptoms of dry eye disease by maintaining a stable tear film and protecting the epithelium from desiccation.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Ocular irritation
- Blurred vision
- Eye discomfort
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs (EARLY_PHASE1)
- Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis (PHASE4)
- Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops (NA)
- The Vaginal Health Trial (PHASE3)
- PK/PD of Single Dose Dapivirine Vaginal Film (PHASE1)
- Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG- 400 based artificial tear CI brief — competitive landscape report
- PEG- 400 based artificial tear updates RSS · CI watch RSS
- Bp Consulting, Inc portfolio CI